Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
2026 · 1st Quarter (Jan 1 - Mar 31)
ELI LILLY AND COMPANY
Filed by FEROX STRATEGIES.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- FEROX STRATEGIES
- Client
- ELI LILLY AND COMPANY
- Filing UUID
- 2a6ec9f9-6acc-439f-897e-fd1621d3312d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.